Pharmacodynamics

Human growth hormone (HGH), also known as somatropin, exerts its effects primarily through binding to the growth hormone receptor (GHR), a member of the cytokine receptor superfamily. The GHR is widely distributed across tissues including liver, muscle, adipose tissue, and bone. Upon binding, HGH induces receptor dimerization and activation of the JAK2-STAT5 signaling pathway. This leads to phosphorylation of STAT5, which translocates to the nucleus and activates transcription of insulin-like growth factor-1 (IGF-1) and other growth-promoting genes. IGF-1 production, primarily in the liver, mediates many of the anabolic effects of GH through autocrine and paracrine mechanisms. In muscle tissue, GH stimulates protein synthesis, amino acid uptake, and satellite cell activation, contributing to muscle growth and repair. The hormone also activates hormone-sensitive lipase in adipocytes, promoting lipolysis and fat oxidation while simultaneously inhibiting lipogenesis. GH exhibits direct anti-insulin effects on glucose metabolism, increasing gluconeogenesis and reducing glucose uptake in peripheral tissues. The temporal pattern of GH action involves both acute effects (within hours) such as lipolysis and metabolic changes, and chronic anabolic effects (days to weeks) mediated primarily through IGF-1. Peak tissue responses typically occur 4-8 hours post-administration, with sustained elevations in IGF-1 lasting 12-24 hours.

Pharmacokinetics

Somatropin is administered via subcutaneous injection due to its protein nature, which would be degraded if taken orally. Following subcutaneous administration, bioavailability ranges from 70-90%, with peak serum concentrations achieved within 2-6 hours. The hormone distributes rapidly throughout the body, with a volume of distribution of approximately 0.07 L/kg, indicating primarily extracellular distribution. Protein binding is minimal, allowing for rapid tissue penetration and receptor binding. GH metabolism occurs primarily in the liver and kidneys through proteolytic cleavage and deamidation. The elimination half-life varies by route of administration, with subcutaneous injection yielding a half-life of 3-5 hours, compared to 20-30 minutes following intravenous administration. Renal clearance accounts for approximately 0.4 L/hr/kg, with both glomerular filtration and active tubular secretion contributing to elimination. Age-related changes in pharmacokinetics include reduced clearance in elderly populations, while renal or hepatic impairment can significantly prolong elimination. The relatively short half-life necessitates daily administration for therapeutic applications, typically administered in the evening to mimic physiological nocturnal GH release patterns.

Clinical Data

Extensive clinical research has established somatropin's efficacy in FDA-approved indications including growth hormone deficiency in children and adults, with robust evidence for improved body composition, bone density, and quality of life measures. In adult GH deficiency studies, treatment consistently demonstrates reduced visceral adiposity, increased lean body mass, and improved exercise capacity over 6-12 months of therapy. Preclinical studies in animal models have shown enhanced muscle protein synthesis, accelerated wound healing, and improved metabolic parameters. However, clinical evidence for performance enhancement in healthy individuals remains limited and controversial, with studies showing modest improvements in lean mass but inconsistent effects on strength or athletic performance. The FDA has approved somatropin for specific medical conditions including Prader-Willi syndrome, Turner syndrome, chronic kidney disease, and muscle wasting in HIV patients. Long-term safety data from pediatric growth studies spanning decades indicate generally good tolerability, though potential risks include glucose intolerance, fluid retention, and joint pain. Current regulatory status restricts use to legitimate medical indications, with off-label use for anti-aging or performance enhancement lacking regulatory approval. Ongoing research focuses on optimizing dosing regimens, investigating combination therapies, and developing longer-acting formulations to improve patient compliance and outcomes.

References

1. Growth hormone, IGF-I, and the metabolic syndrome — Bartke A et al., Journal of Clinical Investigation (2013)
2. Consensus guidelines for the diagnosis and treatment of growth hormone deficiency in childhood and adolescence — Clayton PE et al., Hormone Research in Paediatrics (2007)
3. Effects of human growth hormone in men over 60 years old — Rudman D et al., New England Journal of Medicine (1990)
4. Growth hormone and physical performance — Meinhardt U et al., European Journal of Endocrinology (2010)